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Summary 
Inflammatory Bowel Disease (IBD) is a chronic disabling disease of the 
gastrointestinal tract. The disease is strongly associated with limited performance 
of everyday activities and restrictions in work and employment, recreation and 
relationships to others, as well as reduced quality of life. Thus, suffering from IBD 
includes not only impairments of body functions and body structures but also 
limitations of activities in everyday life and restrictions in participation. 
Consequentially, a comprehensive approach of functioning and disability is 
required when addressing the impact of IBD. 
There are a large number of outcome measures that assess health status 
problems of persons with IBD. Many of these measures used in clinical practice or 
research are classification or scoring systems that refer to disease activity and 
symptomatology in IBD in terms of impaired body functions and structures (e.g., 
Crohn's Disease Activity Index (CDAI), Harvey Bradshaw Index). Hence, disability 
and functioning from a comprehensive point of view are poorly addressed in these 
measures and do not cover the whole spectrum of problems persons with IBD 
have to deal with. Patient-reported outcome measures (PROMs) offer the 
possibility to assess health status problems from the perspective of persons 
suffering a disease. The number of IBD-specific PROMs which focus on aspects of 
functioning, disability and health (e.g., Inflammatory Bowel Disease Questionnaire 
(IBDQ-32), Rating Form of IBD Patient Concerns (RFIPC), Inflammatory Bowel 
Disease Stress Index (IBDSI)) has increased over the last years so that the 
selection of appropriate PROMs for specific purposes or subpopulations has 
become a challenge for clinicians and researchers. However, up to now it remains 
unclear whether currently used IBD-specific PROMs cover the whole spectrum of 
functioning and disability. 
This doctoral thesis examines the content of IBD-specific PROMs using the 
International Classification of Functioning, Disability and Health (ICF) as a 
reference to facilitate the selection of appropriate PROMs by clinicians and 
researchers. The ICF endorsed by the World Health Organization as a common 
language of functioning and disability is a proven and useful tool for the 
examination and comparison of the content of outcome measures. 
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A systematic literature review was performed to identify IBD-specific PROMs used 
in studies involving persons with IBD. Searches were performed in the literature 
databases Medline®, EMBASE, PsycINFO, CINAHL and CENTRAL. Searches 
were limited to English articles published between 1999 and 2009. Eligibility 
checks of abstracts and full-texts were performed applying pre-defined inclusion 
and exclusion criteria. IBD-specific PROMs reported in the selected studies, as 
well as study-related characteristics, were extracted. The items of the identified 
PROMs were translated (“linked”) to the most specific ICF category according to 
standardized and established linking rules. The linked ICF categories provided the 
basis of the descriptive analysis and the comparison of the content of the different 
PROMs presented in this thesis. 
A total of 9,728 papers were identified by the searches in the five electronic 
databases. The randomly selected abstracts of 2,579 papers were checked on 
inclusion and exclusion criteria according to the defined eligibility criteria. Based 
on this abstract check, 221 studies were identified for further analysis. Screening 
these 221 full-text articles, 46 studies were finally selected that reported the use of 
IBD-specific PROMs. The following eight IBD-specific PROMs were identified: 
Cleveland Global Quality of Life (Faszio Score) (CGQL), Inflammatory Bowel 
Disease Quality of Life Questionnaire (IBDQOL), IBDQ-32, IBDSI, Inflammatory 
Bowel Disease Questionnaire – short form (IBDQ-9), RFIPC, Short Inflammatory 
Bowel Disease Questionnaire (SIBDQ) and Work Productivity and Activity 
Impairment: Crohn’s Disease (WPAI:CD). In total, these eight IBD-specific PROMs 
included 129 items which were linked to ICF categories. The most frequently 
identified ICF categories are 'b1300 Energy level' and 'b5254 Flatulence' 
(IBDQOL, IBDQ-32, IBDQ-9, RFIPC and SIBDQ), as well as 'd920 Recreation and 
leisure' (IBDQOL, IBDQ-32, IBDSI, IBS-QOL and SIBDQ). Most of the analyzed 
questionnaires do not cover a wide range of aspects needed to assess functioning 
and disability from a comprehensive perspective; they only focus on selected 
aspects of functioning and disability of persons with IBD (e.g., emotional functions, 
pain, intimate relationships and remunerative employment).  
This doctoral thesis provides an item-based examination of the content of IBD-
specific PROMs using the ICF as a reference. It offers a clear and precise picture 
of the addressed PROMs and their contents and enable physicians and 
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researchers a direct comparison of these contents. The ICF was established as a 
useful framework for examining and comparing IBD-specific PROMs and their 
items with respect to the areas of functioning and disability covered. This 
information can be useful in selecting PROMs for clinical practice, as well as for 
any kind of investigations in which functioning and disability of persons with IBD is 
a relevant study outcome. 
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Zusammenfassung 
Chronisch entzündliche Darmerkrankungen (CED) sind eine stark 
beeinträchtigende Erkrankung des Gastrointestinaltrakts. Patienten, die an dieser 
Erkrankung leiden, sind nicht nur in ihrem Alltag, sondern auch hinsichtlich 
beruflicher Aktivitäten als auch in ihren Freizeitbeschäftigungen und in ihrem 
Sozialleben eingeschränkt. CED gehen somit nicht nur mit Schädigungen von 
Körperstrukturen und Beeinträchtigungen von Körperfunktionen einher, sondern 
auch mit Einschränkungen im Alltag und in der sozialen Teilhabe. Daher ist ein 
umfassender Ansatz notwendig, um die Auswirkung von CED adäquat erfassen zu 
können. 
Es gibt eine Reihe von Erhebungsinstrumenten, mit denen das Outcome bzw. der 
Gesundheitszustand von Patienten mit CED bestimmt werden kann. Die meisten 
dieser Instrumente, die in Klinik oder Forschung herangezogen werden, sind 
Klassifikations- oder Scoringsysteme, die die Schwere der Erkrankung und die 
entsprechenden Symptome im Sinne von funktionellen Beeinträchtigungen 
messen (z.B. Crohn's Disease Activity Index (CDAI), Harvey Bradshaw Index). 
Eine umfassende Krankheitsauffassung und -perspektive kommt in solchen 
Instrumenten nicht zum Tragen und kann somit nicht das ganze Spektrum von 
Problemen, mit denen CED-Patienten konfrontiert werden, aufzeigen. 
Patientenfragebögen dagegen bieten die Möglichkeit, eine Erkrankung aus der 
Sicht eines Betroffenen einzuschätzen und zu beurteilen. Die Zahl der CED-
spezifischen Patientenfragebögen, die sich auf Aspekte wie Funktionsfähigkeit und 
Gesundheit konzentrieren (z.B. Inflammatory Bowel Disease Questionnaire 
(IBDQ-32), Rating Form of IBD Patient Concerns (RFIPC), Inflammatory Bowel 
Disease Stress Index (IBDSI)) hat in den letzten Jahren stark zugenommen, so 
dass die Auswahl von adäquaten patientenbezogenen Messinstrumenten für 
spezifische Fragestellungen eine Herausforderung für Kliniker und 
Wissenschaftler darstellt. Es wurde bisher noch nicht untersucht, welches dieser 
patientenbezogenen Messinstrumente das ganze Spektrum von Funktionsfähigkeit 
und Gesundheit abdeckt.  
Diese Dissertation untersucht den Inhalt von CED-spezifischen 
Patientenfragebögen. Die Internationale Klassifikation der Funktionsfähigkeit, 
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Behinderung und Gesundheit (ICF) dient hierbei als Grundlage, um einen 
Überblick über die Inhalte der Fragebögen zu ermöglichen und somit die Auswahl 
für Kliniker und Wissenschaftler zu erleichtern. Die ICF, ein Klassifikationssystem 
der Weltgesundheitsorganisation (WHO) zur Beschreibung von Funktionsfähigkeit 
und Gesundheit, ist ein etabliertes und nützliches Instrument, um den Inhalt von 
Messinstrumenten zu untersuchen und zu vergleichen. 
Mittels eines systematischen Literaturreviews wurden CED-spezifische 
Patientenfragebögen bestimmt, die in CED-Studien verwendet wurden. Die Suche 
wurde in folgenden Datenbanken durchgeführt: Medline®, EMBASE, PsycINFO, 
CINAHL und CENTRAL. Die Suche wurde beschränkt auf Studien in englischer 
Sprache, die zwischen 1999 und 2009 veröffentlicht wurden. Abstrakts und 
Volltexte wurden anhand von zuvor festgelegter Auswahlkriterien gescreent. CED-
spezifische Fragebögen, die in den eingeschlossenen Studien verwendet wurden, 
und studienbezogene Charakteristika wurden identifiziert und dokumentiert. Die 
Items der identifizierten Fragebögen wurden in die Sprache der ICF übersetzt, d.h. 
zu ICF-Kategorien gelinkt. Dieses Linking der Fragebogen-Items wurde gemäß 
standardisierter und etablierter Richtlinien vorgenommen. Die gelinkten ICF-
Kategorien bildeten die Basis der in dieser Dissertation beschriebenen Analyse 
und dem Inhaltsvergleich der verschiedenen CED-spezifischen 
Patientenfragebögen. 
Insgesamt wurden 9728 Studien durch Suche in den fünf elektronischen 
Datenbanken identifiziert. Nach Ziehung einer Zufallsstichprobe wurden 2579 
Studien nach zuvor definierter Auswahlkriterien auf ihre Ein- bzw. 
Ausschlusskriterien hin geprüft. Nach Lesen der Abstracts verblieben 221 Studien, 
die inhaltlich einer genaueren Untersuchung bedurften. Ausgehend von diesen 
221 Studien wurden schließlich 46 selektiert, bei denen die Verwendung von CED-
spezifischen Patientenfragebögen berichtet wurde. In diesen Studien wurden 
folgende acht Instrumente benannt: Cleveland Global Quality of Life (Faszio 
Score) (CGQL), inflammatory Bowel Disease Quality of Life Questionnaire 
(IBDQOL), IBDQ32, IBDSI, Inflammatory Bowel Disease Questionnaire – 
Kurzversion (IBDQ-9), RFIPC, Short Inflammatory Bowel Disease Questionnaire 
(SIBDQ) and Work Productivity and Activity Impairment: Crohn’s Disease 
(WPAI:CD). Insgesamt enthalten diese acht CED-spezifischen Fragebögen 129 
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Items, die zur ICF gelinkt werden konnten. Folgende ICF-Kategorien wurden in 
den untersuchten Fragebögen am häufigsten identifiziert: 'b1300 Ausmaß der 
psychischen Energie' und 'b5254 Flatulenz' (IBDQOL, IBDQ-32, IBDQ-9, RFIPC 
and SIBDQ) sowie 'd920 Erholung und Freizeit' (IBDQOL, IBDQ-32, IBDSI, IBS-
QOL and SIBDQ). Die meisten Fragebögen decken allerdings kein breites 
Spektrum an Aspekten ab, die notwendig sind, um Funktionsfähigkeit von einer 
umfassenden Perspektive aus zu beschreiben, sie fokussieren dagegen nur auf 
einzelne Aspekte von Funktionsfähigkeit, wie z.B. emotionale Funktionen, 
Schmerz, intime Beziehungen und Erwerbstätigkeit. 
Die vorliegende Doktorarbeit berichtet über eine Item-basierte Inhaltsanalyse von 
CED-spezifischen Patientenfragebögen unter Verwendung der Sprache der ICF-
Klassifikation. Sie bietet eine präzise Beschreibung der analysierten Fragebögen 
und deren Inhalte und ermöglicht somit Klinikern und Wissenschaftlern einen 
direkten Vergleich der Inhalte der verschiedenen Fragebögen. Die ICF diente 
hierbei als ein nützliches Rahmenkonzept, um die Untersuchung und den 
Inhaltsvergleich der CED-spezifischen patientenbezogenen Fragebögen und 
deren Items hinsichtlich der Bereiche Funktionsfähigkeit und Gesundheit 
vorzunehmen. Diese Informationen können bei der Auswahl von 
Patientenfragebögen für die klinische Praxis als auch für Untersuchungen und 
Studien der unterschiedlichsten Art, bei der die Erfassung von Funktionsfähigkeit 
und Gesundheit von CED-Patienten ein Studienoutcome darstellt, von großem 
Nutzen sein.  
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1. Introduction 
1.1 Inflammatory Bowel Diseases1 
Inflammatory Bowel Disease (IBD) is a chronic disabling disease of the 
gastrointestinal tract.1,2 The most common entities are Crohn's disease and 
ulcerative colitis with symptoms like diarrhea, rectal urgency, abdominal discomfort 
and weakness.3,4 Symptoms may not be limited to the intestine but can also have 
extraintestinal manifestations affecting e.g. the skin, joints and eyes.5  
 
 
1.1.1 Prevalence and pathophysiology of inflammatory bowel disease 
Countries of the northern hemisphere like Europe and the United States have the 
highest prevalence with 44 patients per 100 000. Countries of the southern 
hemisphere like Asia and Africa have a much lower prevalence of 4 per 100 000.6 
When people migrate to more northern and developed countries they are subject 
to the local incidence rates. Crohn’s disease is more often diagnosed in Jewish 
people with ulcerative colitis being three to five times more prevalent.7 
 
A positive family history is the largest independent risk factor for the disease. The 
estimated lifetime risk of developing IBD for a first degree relative is between 4.8% 
and 5.2%.8 A German nationwide study about the epidemiology of IBD shows that 
in monozygotic twins 35% were concordant for Crohn's disease and 16% for 
ulcerative colitis. In dizygotic pairs 3% with Crohn’s disease and 2% dizygotic 
twins with UC were concordant for the disease.9 Ulcerative colitis and Crohn’s 
disease are polygenic and have susceptibility regions on 12 different 
chromosomes. Some of them have been renamed IBD 1-9. Chromosome 6 (IBD3) 
has been linked to all IBDs regardless of the geographic location of the person. 
More specific gene locations with an array of polymorphisms have been identified 
on chromosome 16 as CARD15 (NOD2). This location is exclusively associated 
with Crohn’s disease in white populations.  
                                                 
1 The information about IBD derive mainly from Baumgart D et al (6) and Mayer E, Irritable Bowel 
Syndrome, N Engl J Med 2008; 358; 1692-1699 and Baumgart D et al. (41) 
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As the prevalence is so different between countries of the northern and southern 
hemisphere a major focus has been directed to differences in life style. 
Breastfeeding, the consumption of carbohydrates and the intake of 
polyunsaturated fats or margarine have been implicated. But so far no final 
conclusions about the role of nutrition in IBD can be made. As there is a low 
incidence of IBD in developing countries it has been suggested that excessive 
sanitation might limit exposure to environmental antigens and might impair the 
maturation of the mucosal immune system. This may result in inappropriate 
immune responses when re-exposed to these antigens later in lifetime. In addition, 
chronic stress and depression may increase the probability in patients with 
dormant disease. Although IBD is more common after gastrointestinal infection, no 
specific causative agent has so far been identified. This emphasizes the notion 
that the basic problem of IBD is an impaired handling of microbial antigens by the 
intestinal immune system. 
 
In the normal gut there is an epithelial barrier that consists of a polarised single 
layers covered with mucus that contains secretory IgA and glycocalyx. Fluxes 
through the intestinal epithelium proceed through a transcellular route. Antigen 
recognition and immune regulation are mediated via a family of the toll like 
receptors. Toll like receptors trigger antimicrobial responses that lead to activation 
of nuclear transcription factors and induction of the inflammatory cytokine 
cascade. This may be the reasons why prolonged non-steroidal anti-inflammatory 
drugs (NSAID) use but not aspirin intake is associated with an increased risk for 
IBD10. The gut mucosa also includes lymphoid tissue with T cells, B cells, 
granulocytes, mast cells, natural killer cells and natural killer T-cells which are 
located in the lamina propria. Antigens and microbes are channelled through the 
epithelial barrier to those lymphoid cells, where they meet dendritic cells and 
macrophages. Dendritic cells are able to differentiate in their response between 
pathogens and normal intestinal flora by expressing the entire spectrum of toll like 
receptors.  
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The defective mucosal immune system in IBD results in an inappropriate response 
to the normal gut flora. Experimental and clinical evidence suggests the following 
mechanisms: 
(1) T-cell mediated disruption of tight junction protein as well as enteric neuron 
dysfunction may increase gut permeability. This may precede the clinical onset 
of disease and be associated with a CARDIS15 3020insC mutation. 
(2) Patients with IBD have different expression of toll like receptors. TLR 3 is 
significantly downregulated in Crohn’s disease; TLR4 is upregulated in Crohn’s 
disease and ulcerative colitis.  
(3) Antigen recognition by dendritic cells is disturbed. Dendritic cells incorrectly 
recognize normal gut bacteria and induce a proinflammatory immune 
response normally directed at pathogens.  
(4) Atypical antigen-presenting cells may become potent T-cell activators in 
patients with inflammatory bowel disease. It has been demonstrated in 
patients with IBD that intestinal-epithelial cells might be transformed into 
functional antigen-presenting cells.  
(5) Patients with Crohn’s disease have an altered clearance of over-reactive T-cell 
populations thus fuelling the inflammatory process.  
(6) In Crohn’s disease the balance of regulatory and effector cells is disturbed 
which perpetuates inflammation.  
(7) In patients with IBD psychosocial stress might trigger the inflammatory 
cascade through neuroimmunological interaction by shifting the balance of the 
autonomic nervous system. Whereas the vagus has a substantial inhibitory 
effect and attenuation of the systemic inflammatory response, the activation of 
the sympathetic system in ulcerative colitis can cause an increased colonic 
paracellular permeability.  
 
As a result of these mechanisms there is migration of inflammatory cells from the 
capillaries into the intestinal mucosa. Proinflammatory cytokines (IL 1, TNF alpha) 
upregulate the expression of adhesion molecules ligands on the vascular 
endothelium of the mucosal blood vessels promoting leukocyte adhesion and 
extravasation into the tissue.11,12 In this way, a multitude of aggressive metabolites 
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and mediators accumulate in the mucosa resulting in tissue damage. A vast array 
of mediators promotes fibroblast growth with collagen secretion and stricture 
formation. To terminate or prevent the initiation and perpetuation of the 
inflammatory cascade a specific approach aimed at the above mentioned 
mechanism is needed. 
 
 
1.1.2 Clinical aspects 
Ulcerative colitis 
Ulcerative colitis is a recurrent non-transmural inflammatory disease that is 
restricted to the colon. Proctitis, left-sided colitis or pancolitis can occur. Ulcerative 
colitis is a clinical diagnosis confirmed by objective findings from endoscopic and 
histological examinations. The disease is typically described as mild (up to four 
bloody stools per day), moderate (four to six bloody stools per day or severe (more 
than six bloody stools as well as fever, tachycardia and anaemia). The final stage 
is a fulminant colitis with more than ten stools, continuous bleeding, abdominal 
tenderness and colonic dilation progressing to toxic megacolon. The disease is 
characterized by alternating relapses and remissions. Overall, patients with 
ulcerative colitis have a normal life expectancy. 
  
Crohn’s disease 
Crohn’s disease is a relapsing, transmural inflammatory disease of the 
gastrointestinal mucosa that can affect the entire gastrointestinal tract from the 
mouth to the anus. Complications include strictures, abscesses or fistulas. At 
diagnosis, the disease is located in the terminal ileum in 47%, the colon in 28%, 
the ileocolon in 21% and the upper gastrointestinal tract in 3%. The clinical 
presentation is dependent on disease location and can include diarrhoea, 
abdominal pain, fever, bowel obstruction, as well as passage of blood or mucus or 
both. 
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There is no definitive diagnostic test for Crohn’s disease. The disease activity is 
described as mild to moderate (patient tolerating oral food), moderate to severe 
(fever, weight loss, abdominal pain, anaemia) and severe to fulminant (high fevers, 
vomiting, intestinal obstruction, cachexia, abcess). In the course of the disease the 
anatomical location is stable, but it may change from non-stricturing to either 
stricturing (27%) or penetrating (29%) disease. After 20 years most patients with 
Crohn’s disease will require surgery. The life expectancy is slightly reduced. 
 
Complications and manifestations in Crohn’s disease and ulcerative colitis 
In addition, there are neoplastic complications of IBD including colon cancer in 
patients with ulcerative colitis and Crohn’s disease. A screening colonoscopy with 
multiple biopsies is indicated 8 to 10 years after onset of ulcerative colitis, 
decreasing the interval to 1 to 2 years in patients with extensive disease. After 20 
years of onset, yearly controls are recommended. Patients with primary sclerosing 
cholangitis have an increased risk of developing colorectal cancer and should be 
checked on a yearly basis. Colectomy is indicated in patients with ulcerative colitis 
with high-grade dysplasia or evidence of colorectal cancer. In patients with Crohn’s 
disease the risk of colorectal cancer is similar to that for ulcerative colitis. 
 
Furthermore, there is to mention that there are also extraintestinal manifestations 
of IBD. They include in the head area uveitis, episcleritis and sensoneural hearing 
loss and in the trunk area pleuritis, myocarditis, sclerosing cholangitis, 
nephrolithiasis, pancreatitis, ankylosing spondylitis and sacroileitis. In the 
extremities arthritis, erythema nodosum, pyoderma gangrenosum and tendinitis 
can be observed. Overall, patients with IBD have a higher risk of venous 
thromboembolism (2.6 per 1000 person-years).13 At the time of a flare, this 
increase in risk is much more prominent (9.0 per 1000 person-years).13 Thus, trials 
of primary prophylaxis of venous thromboembolism are warranted to find out 
whether this important complication can be prevented.13  
 
Abdominal pain is a common symptom of IBD. Pain may arise from different 
mechanisms like partial blockade and gut distention, as well as severe intestinal 
inflammation. Even without acute flare a significant percentage of patients 
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continue to experience pain. Current evidence suggests that sensory pathways 
sensitize during inflammation, leading to persistent changes in afferent neurons 
and central nervous system pain processing. Pain processing and the activation of 
sensory pathways are modulated by arousal, emotion, and cognitive factors. 
Considering the high prevalence of iatrogenic as well as neuropsychiatric 
comorbidities, these central modulating factors may significantly contribute to the 
clinical manifestation of chronic pain. 
 
Differential diagnosis: IBD versus inflammatory bowel syndrome (IBS) 
IBD has to be separated from IBS which is characterized by chronically recurring 
abdominal pain or discomfort and altered bowel habits. It is much more common 
with a worldwide prevalence of 10-15%.14 In the absence of detectable organic 
causes, IBS is referred to as a functional disorder, which is defined by symptom-
based diagnostic criteria known as the “Rome criteria”. IBS-like symptoms develop 
in approximately 10% of adult patients after bacterial or viral enteric infections. 
Risk factors for the development of post-infectious IBS include female sex, a 
longer duration of gastroenteritis and the presence of psychosocial factors like 
major life stress at the time of infection and somatization. Thus, IBS is often 
described as a “brain-gut disorder”. Its pathophysiology remains uncertain. 
Dysregulation of the gut-based serotonin signaling system, alterations in immune 
activation of the mucosa and intestinal microflora may contribute to symptoms of 
IBS. Some of these symptoms may be similar to celiac sprue, microscopic and 
collagenous colitis and atypical Crohn’s disease.  
 
 
1.1.3. Functioning and health in IBD 
The disease is strongly associated with limited performance of every-day activities 
and restrictions in work and employment, recreation activities and relationships 
with others. Rubin et al. showed that patients with ulcerative colitis found living 
with their disease to be a daily struggle (61%), more so than patients with asthma 
(33%) or migraine headaches (45%).15 A significantly greater proportion of patients 
with ulcerative colitis (60%) reported that their disease had ruined (‘wrecked’) 
important moments of their lives compared to patients with asthma (25%) or 
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rheumatoid arthritis (48%). More patients with ulcerative colitis felt that their 
disease was controlling their lives (53%) than patients with any of the other 
surveyed diseases. Furthermore, patients with ulcerative colitis reported that their 
disease caused difficulties with travel and participation in recreational activities or 
public events.15 With regard to impact of every-day activities, three times the 
number of IBD patients reported having reduced activity (often or sometimes) at 
work and at home compared to a non-IBD community sample. Half of those with 
IBD reported significantly greater interference in other activities as well. Even 
those with inactive IBD reported significantly greater interference (reduction of 
activity) across several domains compared to the (non-IBD) community sample.16 
Muller et al. showed that a very large proportion of patients with IBD perceive a 
negative impact of their disease on many aspects of their sexuality. Specifically, 
female gender and surgery for IBD are risk factors for a negative view of body 
image, libido and frequency of sexual activity. In addition, 88.5 percent of IBD 
patients reported that their quality of life was impaired by IBD.45 Thus, suffering 
from IBD includes not only impairment of body functions and structures but also 
limitations in activities of every-day activities and restrictions in participation.  
 
 
1.1.4. Treatment 
Treatment of ulcerative colitis 
First-line therapy for patients with mild to moderate ulcerative colitis is 5-
aminosalicylic acid as rectal and oral drugs. Doses of 1500-2400 mg per day of 
oral 5-aminosalicylic acid will be effective in most patients. Proctitis and left-sided 
ulcerative colitis might respond better to rectal mesalazine or corticosteroids. 
Patients who do not respond to oral or rectal therapy should be treated with oral 
corticosteroids. In difficult cases infliximab, a chimeric monoclonal antibody to 
tumour-necrosis factor (TNF) can be tried. 
  
First-line therapy for the maintenance of remission is oral mesaline with a minimal 
oral dose of 1500 mg per day. Further options are ciclosporin, azathioprine and 
mercaptopurine. 
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Surgical management is indicated in patients with bowel perforation, refractory 
rectal bleeding and toxic megacolon not responsive to medical management. The 
accepted surgical technique is total proctocolectomy with ileal J-pouch-anal 
anastomosis. 
 
Treatment of Crohn’s disease 
First-line therapy for patients with mild to moderate Crohn’s disease is 
sulfasalazine at doses of 3000-4500 mg per day. Mesalazine did not show a 
clinically important treatment effect. The corticosteroid budesonide is given orally 
or via rectum. Its extensive first-pass hepatic metabolism markedly reduces 
systemic side-effects of this corticosteroid. A 9 mg per day dose budesonide is 
more effective than 4000mg per day oral 5-aminosalicylic acid and has similar 
efficacy to prednisolone in active Crohn’s disease.17 Antibiotics failed to show 
efficacy for induction of remission. Thus, sulfasalazine can be recommended for 
induction therapy in patients with mildly to moderately active disease with colonic 
involvement and budesonide in patients with ileal or right colonic involvement or 
both. Patients who do not respond are treated with oral prednisone 40 mg per day. 
About 44% of patients with Crohn’s disease need corticosteroids to achieve 
remission. When these treatments fail monoclonal antibodies to TNF like infliximab 
or adalimumab can be tried. 
  
For maintenance of remission 5-aminosalicyclic acid, azathioprine, 
mercaptopurine or methotrexate are used. Because of the slow onset of these 
drugs they are mainly used as maintenance rather than induction agents. These 
drugs should generally be combined with fast-acting drugs like budesonide, 
conventional steroids and/or infliximab. The latter is effective for maintenance of 
remission, steroid sparing and mucosal healing in patients who are unable to 
maintain remission with the other drugs. 
  
 
For management of fistulas in patients with Crohn’s disease antibiotic therapy with 
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ciprofloxacin 1000 mg per day or metronidazole is the first-line treatment. In 
addition, azathioprine or mercaptopurine are used as a second-line treatment. 
When these therapies fail, infliximab or adalimumab can be added.  
Indications for surgery include formation of strictures leading to bowel obstruction, 
internal fistulas complicated by abdominal abscess formation, as well as 
endovesical and/or entrocutaneous fistulas.  
 
Future therapies for IBD 
Future therapies for IBD include:  
(1) the blockade of TNF by infliximab, adalimumab and certilizumab and possibly 
etanercerpt;  
(2) The modulation of other key cytokines by the humanised interferon-gamma 
antibody fontolizumab; 
(3) The blockade of T cells by the humanised anti-CD3 antibody visilizumab; 
(4) The blockade of inflammatory cell migration and adhesion by the alpha 4-
integrin natalizumab. 
Many of the new therapies for IBD using immunosuppressants and -modulators 
are associated with potentially severe side effects ranging from cutaneous and 
pulmonary hypersensitivities (pneumonitis), bone marrow depression, hepatic 
disease to demyelination, drug-induced lupus, heart failure serious infections, non-
Hodgkin`s lymphoma and solid tumour malignancies. 
 
 
1.2 Outcome measures in IBD 
There are a large number of outcome measures assessing health-status problems 
of persons with Crohn’s disease or ulcerative colitis.18 Many of these measures 
used in clinical practice or research are classification or scoring systems that refer 
to disease activity and symptomatology in IBD in terms of impaired body functions 
and structures. The Crohn's Disease Activity Index (CDAI)19 for example is a 
measurement to quantify the symptoms of patients with Crohn’s disease. The 
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questionnaire includes components as the number of liquid or soft stools per day, 
abdominal pain or the number of complications. The CDAI is focused on the 
symptoms of Crohn’s disease, so does the Harvey Bradshaw Index20, another 
often used measurement to quantify the symptoms of Crohn’s disease. The 
Harvey Bradshaw Index is also concentrated on clinical symptoms (number of 
liquid stool, abdominal pain, abdominal mass). The Truelove and Witts Severity 
Index21 is another established measurement to assess the disease activity, 
composed of six variables as blood in stool, temperature, pulse, haemoglobin and 
erythrocyte sedimentation rate.  
 
The CDAI has been used to measure Crohn's activity for many decades. The 
development of the CDAI is reviewed and its reliability and validity are examined. 
Instruments used to assess Crohn's disease that were developed subsequent to 
the CDAI, including the Harvey-Bradshaw Index, are similarly reviewed.22 In these 
measurements disability and functioning from a comprehensive point of view are 
poorly addressed and do not cover the whole spectrum of problems persons with 
IBD have to deal with.23,24 
 
Patient-reported outcome measures (PROMs) provide the possibility to assess 
health-status problems from the perspective of persons suffering from a disease. 
The number of IBD-specific PROMs which focus on aspects of functioning, 
disability and health (e.g. Inflammatory Bowel Disease Questionnaire (IBDQ-32),25 
Rating Form of IBD Patient Concerns (RFIPC),26 Inflammatory Bowel Disease 
Stress Index (IBDSI)27) has increased over the last years so that the selection of 
the appropriate PROMs for specific purposes or subpopulations has become a 
challenge. However, up to now it has remained unclear whether these PROMs 
cover the whole spectrum of functioning and disability. 
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1.3 The International Classification of Functioning, Disability and 
Health 
A comprehensive, efficient treatment for patients requires an interdisciplinary 
collaboration between the involved health professionals and other relevant 
instances. To assure the most efficient collaboration a common language for 
describing health and health-related states which can be used and understood by 
all parties is needed. The International Classification of Functioning, Disability and 
Health (ICF) provides such an unified and standard language28. Since its approval 
in May 2001 by the fifty-fourth World Health Assembly (WHA), which is a member 
of the WHO family of International Classification, all member states of the World 
Health Organization (WHO) are urged to implement the ICF in clinical practice. 
The ICF establishes a universal and generally accepted language for the 
description of health conditions and health-related states and a globally agreed-
upon framework for all health professionals as well as researchers, policy makers 
and the public.28 
 
The ICF is based on an integrative and functional model of health that provides a 
holistic, multidimensional and interdisciplinary understanding of health and health-
related states. It is divided into two parts: Functioning and Disability and 
Contextual Factors. According to the ICF Functioning and Disability refer to the 
ICF components Body Functions, Body Structures and Activities & Participation in 
life situations. Body Functions are defined as physiological and psychological 
functions of the body system whereas Body Structures contain the anatomical 
structures of the body like organs, limbs and their components. The component 
Activities & Participation includes all domains which are associated with the 
aspects of functioning from individual and societal perspective. Activity means the 
execution of something and participation the involvement in situations. The 
components of the part Functioning and Disability can be used to describe 
problems of patients like impairments of Body Functions and Body Structures, 
limitations of Activities and restrictions of Participation as well as to describe non-
problematic aspects of health and health-related states. In this context, functioning 
characterizes the positive aspects and disability the negative aspects of the 
interaction between an individual with a health condition and its contextual factors. 
19 
 
The part Contextual Factors includes the components Environmental Factors and 
Personal Factors (figure1). Environmental Factors can have an impact on all 
components of Functioning and Disability and include the physical, social and 
attitudinal environment of a person, which can be facilitating or hindering for the 
individual. Personal Factors are e.g. gender, race, age, lifestyle, habits, coping 
styles, and social background of the individual.  
Health condition
(disorder or disease)
ActivitiesBody Functions and 
Structures
Participation
Environmental 
Factors
Personal
Factors  
 
 
Figure1: Structure of the International Classification of Functioning, Disability and Health 
 
The construction of the ICF is hierarchical. Within each component there is a list of 
so-called ICF categories which are the units of the classification28. ICF categories 
are part of chapters which constitute the first level of precision. The categories are 
denoted by unique alphanumeric codes composed by a letter that refers to the 
components of the classification (b: Body Functions; s: Body Structures; d: 
Activities & Participation; e: Environmental Factors) and followed by a numeric 
code starting with the chapter number (one digit), followed by the second level 
(two digits) and the third and fourth level (one digit each) (figure 2). An example 
from the component Body Functions is as follows: 
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Component  b Body functions 
Chapter  first level b 2 Sensory functions and pain 
Categories second level b 280 Sensation of pain 
 third level b 2801 Pain in body part 
 fourth level b 28015 Pain in lower limb 
 
Within each component the categories are arranged in a stem / branch / leaf 
scheme. Consequently, a higher-level (more detailed) category shares the lower 
level category of which it is member. Therefore, when using a higher level category 
it is possible to apply the lower-level category but not vice versa. 
 
Figure 2: Structure of the International Classification of Functioning, Disability and Health; 
hierarchical arrangement 
 
 
Altogether, the ICF contains more than 1400 categories each allotted into the 
components named above except of the Personal Factors which are not yet 
classified. To facilitate the application of the ICF in clinical practice, the ICF Core 
Sets project was initiated in 2001 by the ICF Research Branch of the WHO 
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Collaboration Centre of the Family of International Classifications (DIMDI) at the 
Ludwig-Maximilians-Universität (LMU) in Munich, Germany, together with the 
Classification, Terminology and Standards Team (CTS Team) at the WHO and an 
increasing number of partner organizations29.  
 
IBD is a disabling disease with various limitations in functioning and it is therefore 
strongly associated with limited performance of every-day activities and a reduced 
quality of life. To asses the health status of patients with IBD there are a large 
number of different outcome measures. Hence, disability and functioning from a 
comprehensive point of view are poorly addressed in most of these measures. 
However, PROMs offer the possibility to assess health status problems from the 
perspective of persons suffering a disease from a more comprehensive point of 
view.  
 
It would be a challenge to describe and examine functioning and disability 
assessed with PROMS using the ICF as a reference. To our knowledge no 
overview has been published so far that examines the content of IBD-specific 
PROMs using the ICF as a reference. Such an overview would facilitate the 
selection of PROMs by clinicians and researchers.  
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2. Objective 
The objective of this doctoral thesis is to examine the content of IBD-specific 
PROMs using the ICF as a reference. The specific aims are (1) to identify IBD-
specific PROMs applied in studies of persons with IBD based on a systematic 
literature review of articles published between 1999 and 2009 and (2) to examine 
which areas of functioning and disability have been addressed by these PROMs 
using the ICF as a reference. 
 
The study reported in this doctoral thesis has already been published in the 
Journal of Crohn’s and Colitis30.  
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3. Materials and methods 
A systematic literature review was performed to identify IBD-specific PROMs used 
in studies of persons with IBD. In our study, PROMs were defined as outcome 
measures in which patients respond to a number of standardized questions asked 
in a paper-pencil form. The items of the identified PROMs were translated 
(“linked”) to the ICF. The linked ICF categories provided the basis of the 
descriptive analysis and the comparison of the content of the different PROMs is 
presented in this thesis. 
 
 
3.1 Systematic literature review: selection of studies 
Searches were performed in the literature databases Medline®, EMBASE, 
PsycINFO, CINAHL and CENTRAL using the search terms 'Colitis, Ulcerative', 
'Crohn Disease', 'Inflammatory Bowel Disease' in MESH terms (if available), title 
and abstract. Searches were limited to English articles published between 1999 
and 2009. 
 
A random sample of about 25% of the abstracts identified in the searches were 
screened and selected based on the following eligibility criteria (Appendix 1 
‘eligibility criteria’):  
(1) human population; 
(2) sample size more than 10 study participants; 
(3) age of at least 18 years; 
(4) main diagnoses of Crohn's disease (regional enteritis), Crohn's disease of 
small intestine, Crohn's disease of large intestine, other Crohn's disease, 
ulcerative colitis, ulcerative (chronic) enterocolitis, ulcerative (chronic) 
ileocolitis, ulcerative (chronic) proctitis, ulcerative (chronic) rectosigmoiditis, 
other ulcerative colitis and ulcerative colitis, unspecified; 
(5) application of IBD-specific PROMs. 
 
Studies should present first-hand data concerning persons with IBD irrespective of 
the type of intervention or setting. In addition, the information in the abstracts was 
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used to assure the inclusion of randomized controlled trials, clinical controlled 
trials, cross-sectional studies, and longitudinal observational studies. Reviews or 
meta-analyses, case reports/case series, primary prevention studies, ecologic 
studies, economic evaluation studies and decision analyses were excluded. 
Comments, letters, editorials, guidelines, conference reports, book chapters and 
dissertations were excluded as well. Screening of abstracts was independently 
performed by the author of this doctoral thesis and a team member of the ICF 
Research Branch. Consensus between the two researchers was achieved to 
decide which abstracts to include. In case of disagreement, pros and cons were 
discussed and if necessary a third researcher (team member of the ICF Research 
Branch) was involved to reach consensus and to decide on the inclusion of 
abstracts. 
 
Full-text articles of the selected studies were retrieved and checked applying the 
same eligibility criteria as reported above.  
 
 
3.2 Extraction of the selected studies 
The IBD-specific PROMs reported in the selected studies, as well as study-related 
characteristics specified in the methods and results section (i.e. sample size, age 
and gender of study participants, main diagnosis, type of intervention), were 
extracted. Quality and plausibility checks of the data extraction were performed. 
Data collected in steps 1 and 2 were documented in a Microsoft® Access 
database. Descriptive statistics were performed to describe the study-related 
characteristics of the selected studies. 
 
 
3.3 Linkage of the identified PROMs 
The items of the identified IBD-specific PROMs were translated (“linked”) to the 
ICF. The linkage procedure started with the identification of linking units contained 
in the items of the PROMs. These linking units were then linked to the most 
specific ICF category according to established linking rules by two independent 
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researchers.31,32 Those linking units which were not sufficient to make a decision 
about the most precise ICF category were assigned 'nd’ (not definable). If a linking 
unit was a personal factor as defined in the ICF, it was assigned 'pf'. If a linking unit 
was not represented by the ICF, the code ‘nc’ (not covered) was chosen.  
 
Consensus between the two independent researchers (the author of this thesis 
and a team member of the ICF Research Branch) was achieved to decide which 
ICF category was to be linked to each linking unit. In case of disagreement, the 
arguments were discussed and if necessary a third researcher (team member of 
the ICF Research Branch) was involved to reach consensus and to decide on the 
final category (Appendix 2 ‘example of a linked PROM’).  
 
Kappa statistics with bootstrapped 95 percent confidence intervals (95% CI) were 
calculated using SAS for Windows V 9.1 (SAS Institute Inc., Cary, NC, USA) to 
analyse the agreement between the two researchers who performed the 
linking.33,34 The values of the Kappa coefficient generally range from 0 to 1, 
whereas 1 indicates perfect agreement and 0 indicates no additional agreement 
beyond what is expected by chance alone. 
 
 
3.4 Content comparison of the linked items 
Absolute frequencies of the linked ICF categories addressed in the items of the 
identified IBD-specific PROMs were calculated using the second level of the ICF 
classification. Therefore, for items linked to a third- or fourth-level ICF category the 
respective second-level category was considered for analysis. Since the ICF is 
organized in a hierarchical scheme, more specific third- or fourth-level categories 
share the attributes of less specific second-level categories. 
 
The steps of this systematic literature review along with their results are presented 
in Figure 3. 
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Figure 3: Procedure of the systematic literature review 
Records identified through database 
searching  
(n = 9,728) 
Screening 
Included 
Eligibility 
Identification 
Records after random sampling 
(n = 2,579) 
Abstracts screened according to defined 
eligibility criteria  
(n = 2,579) 
Records excluded 
(n = 2,358) 
Full-text articles assessed for eligibility  
(n = 221) 
Full-text articles 
excluded 
(n = 175) 
Data extraction of studies including 
IBD-specific PROMs 
(n = 46) 
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4. Results 
4.1 Systematic literature review: selection of studies 
A total of 9,728 papers were identified by the searches in the five electronic 
databases. The randomly selected abstracts of 2,579 papers were checked on 
inclusion and exclusion criteria according to the defined eligibility criteria. Based 
on this abstract check, 221 studies were identified for further analysis. Screening 
these 221 full-text articles, 46 studies reporting the use of IBD-specific PROMs 
were finally selected. The main reason for excluding full-text articles was the use 
of non-IBD specific PROMs (Appendix 3 ‘List of references of included studies’). 
 
 
4.2 Extraction of the selected studies 
Most of the selected studies were pharmaceutical intervention studies (n=19, 
41.3%) followed by nine longitudinal descriptive studies (19.6%) and six cross-
sectional descriptive studies (13.0%). Two retrospective chart review studies 
(4.3%) were included, as well as three undefined intervention studies (6.5%), two 
surgical intervention studies (4.3%) and five psychometric/diagnostic evaluation 
studies (10.9%). 
 
Nearly half of the identified studies (n=19, 41.3%) included persons with the main 
diagnosis Crohn’s disease. The main diagnosis in 16 studies (34.8%) was 
ulcerative colitis. Eleven studies (23.9%) included both diagnoses.  
 
There was a total sample size of 9,396 persons ranging from 12 to 1,156 patients 
in the different individual studies. The total sample included 3,537 females (37.6%, 
missing data n=5 studies). The mean age of the total sample was 39.5 years 
(SD=4.3, 18-79 years; data available in 27 studies). Table 1 shows the countries of 
origin of the included studies. 
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Table 1 Countries of origin of the identified studies (N=46) 
Country of origin n % 
United States of America 11 23.9 
Germany 7 15.2 
Spain 6 13.0 
United Kingdom 4 8.7 
Sweden 4 8.7 
Canada 2 4.3 
Netherlands 2 4.3 
Norway 2 4.3 
Other countries 8 17.4 
 
 
The following eight IBD-specific PROMs were identified in the retrieved studies: 
Cleveland Global Quality of Life (Faszio Score) (CGQL)35, Inflammatory Bowel 
Disease Quality of Life Questionnaire (IBDQOL)36, IBDQ-3225, IBDSI27, 
Inflammatory Bowel Disease Questionnaire – short form (IBDQ-9)37,38, RFIPC26, 
Short Inflammatory Bowel Disease Questionnaire (SIBDQ)39 and Work 
Productivity and Activity Impairment: Crohn’s Disease (WPAI:CD)40. These 
PROMs, their major characteristics and the number of the studies which reported 
their use are shown in Table 2. 
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Table 2 Characteristics and frequencies of the identified IBD-specific PROMs in the included studies (N=46) 
PROMs Frequency 
n (%)
a 
Aim Mode of 
administration 
Number 
of items 
Response 
options 
Time frame Languages 
CGQL Cleveland Global Quality of 
Life (Faszio Score)26 
1 (1.7) Quality of life after pelvicpouch 
surgery 
Self, Interviewer 3 Rating  
0 - 10 
Todayb English 
IBDQOL Inflammatory Bowel 
Disease Quality of Life 
Questionnaire27 
6 (10.0) Quality of life  Self 36 7-point 
responses 
Last two 
weeks 
Multiplec 
IBDQ-32 Inflammatory Bowel 
Disease Questionnaire17 
36 (60.6) Quality of life  Self, Interviewer 32 7-point Likert 
scale 
Last two 
weeks 
Multipled 
IBDQ-9 Inflammatory Bowel 
Disease Questionnaire – 
short form28,29 
1 (2.2) Quality of life  Self, Interviewer 9  Last two 
weeks 
English 
IBDSI Inflammatory Bowel 
Disease Stress Index19 
2 (4.3) Overall life satisfaction, body 
image, relationships, school, 
recreation, sexuality, 
psychosomatic symptomatology 
Self, Interviewer 8 0 (no impact) 
– 
3 (great deal 
of impact) 
Today English 
RFIPC Rating Form of IBD Patient 
Concerns18 
5 (10.9) Worries and concerns 
associated with IBD and its 
treatment 
Self 25 Visual Analog 
Scale 
Today Multiplee 
SIBDQ Short Inflammatory Bowel 
Disease Questionnaire30 
5 (10.9) Quality of life  Self, Interviewer 10 7-point Likert 
scale 
Last two 
weeks 
Multiplef 
WPAI:CD Work Productivity and 
Activity Impairment: 
Crohn’s Disease31 
1 (2.2) Work and activity impairment  Self, Interviewer, 
Telephone 
6 Rating 0-10, 
Number of 
hours 
Last seven 
days 
Multipleg 
a Percentage of studies in which IBD-specific PROMs were applied; more than one PROMs could be applied in one study. 
b At least one year after surgery. 
c Original language: English; translated to Danish, Dutch, Finnish, French, German, Hebrew, Italian, Norwegian, Slovak, Spanish, Swedish. 
d Original language: English; translated to Arabic, Bengali, Bulgarian, Chinese, Czech, Danish, Dutch, Finnish, French, German, Greek, Gujarati, Hebrew, Hungarian, Italian, Japanese, Latvian, 
Lithuanian, Malayalam, Marathi, Norwegian, Polish, Portuguese, Punjabi, Romanian, Russian, Serbian, Sesotho, Slovakian, Spanish, Swedish, Tamil, Telugu, Ukrainian, Urdu for India, Xhosa, Zulu. 
e Original language: English; translated to French, German, Hebrew, Italian, Portuguese, Spanish, Swedish. 
f Original language: English; translated to Arabic, Bengali, Bulgarian, Chinese, Czech, Danish, Dutch, Finnish, French, German, Greek, Gujarati, Hebrew, Hungarian, Italian, Japanese, Latvian, 
Lithuanian, Malayalam, Marathi, Norwegian, Polish, Portuguese, Punjabi, Romanian, Russian, Serbian, Sesotho, Slovakian, Spanish, Swedish, Tamil, Telugu, Ukrainian, Urdu for India, Xhosa, Zulu. 
g Original language: English; translated to Czech, Danish, Dutch, Finnish, French, German Greek, Hungarian, Icelandic, Italian, Japanese, Norwegian, Polish, Portuguese, Slovak, Slovene, Spanish, 
Swedish. 
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4.3 Linkage of the identified PROMs 
In total, the eight IBD-specific PROMs included 129 items. Ninety of them (69.8%) 
were linked to 45 specific ICF categories: 23 Body Functions’ categories (51.1%), 
1 Body Structures’ category (2.2%), 13 categories of the component Activities and 
Participation (28.9%) and 8 Environmental Factors’ categories (17.8%). Twenty-
eight items (21.7%) were linked to Personal Factors (pf) and 11 items to 'nd’ and 
'nc’ (8.5%), respectively. 
 
The Kappa statistic for the linking of the items was 0.61 [95% CI: 0.53 – 0.66]. 
 
 
4.4 Content comparison of the identified PROMs 
In detail, the IBDQ-32 covers the highest (n=24) and the CGQL the lowest number 
of ICF categories (n=1). The most Body Functions’ categories were found in the 
IBDQ-32 (n=14) followed by the IBDQOL (n=12). The following PROMs address 
the most categories of the component Activities and Participation: IBDQOL (n=7), 
IBDQ-32 (n=6) and IBDSI (n=6).  
 
Tables 3 to 5 show the coverage of ICF categories from the components Body 
Functions, Body Structures, Activities and Participation and Environmental Factors 
by the identified PROMs. None of the linked ICF categories are contained in all 
PROMs. The most frequently identified categories are 'b1300 Energy level', 'b5254 
Flatulence' (IBDQOL, IBDQ-32, IBDQ-9, RFIPC and SIBDQ) and 'd920 Recreation 
and leisure' (IBDQOL, IBDQ-32, IBDSI, IBS-QOL and SIBDQ).  
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Table 3 ICF categories of the components Body Functions and Body Structures addressed in IBD-specific PROMs 
ICF categories PROMs 
ICF code ICF title CGQL IBDQOL IBDSI IBDQ-32 IBDQ-9 RFIPC SIBDQ WPAI:CD 
b Body functions  
b1 Mental functions         
b130 Energy and drive functions +    +    
b1300 Energy level  +  + + + +  
b1302 Appetite  +       
b1308 Energy and drive functions, other specified    + +    
b1341 Onset of sleep  +       
b1342 Maintenance of sleep  +  +     
b1343 Quality of sleep    +     
b152 Emotional functions  +  +   +  
b1801 Body image   +      
b2 Sensory functions and pain          
b280 Sensation of pain       +   
b2801 Pain in body part     +   +  
b28012 Pain in stomach or abdomen    +   +  
b5 Functions of the digestive, metabolic and 
endocrine systems         
b5150 Transport of food through stomach and intestines  +  + +    
b525 Defecation functions  +  +  + +  
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Table 3 continued 
ICF categories PROMs 
ICF code ICF title CGQL IBDQOL IBDSI IBDQ-32 IBDQ-9 RFIPC SIBDQ WPAI:CD 
b5253 Faecal continence  +       
b5254 Flatulence  +  + + + +  
b530 Weight maintenance functions  +  +   +  
b535 Sensations associated with the digestive system     + +    
b5350 Sensation of nausea     +    
b5351 Feeling bloated  +  +     
b5352 Sensation of abdominal cramp  +  + +    
b6 Genitourinary and reproductive functions         
b640 Sexual functions      +   
b660 Procreation functions      +   
s Body structures         
s5 Structures related to the digestive, metabolic 
and endocrine systems 
        
s540 Structures of intestine   +  +    
CGQL Cleveland Global Quality of Life (Faszio Score); IBDQOL Inflammatory Bowel Disease Quality of Life Questionnaire; IBDSI IBD Stress Index; IBDQ-32 
Inflammatory Bowel Disease Questionnaire; IBDQ-9 Inflammatory Bowel Disease Questionnaire short form; RFIPC Rating Form of IBD Patient Concerns; 
SIBDQ Short Inflammatory Bowel Disease Questionnaire; WPAI:CD Work Productivity and Activity Impairment: Crohn’s Disease. 
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Table 4 ICF categories of the component Activities and Participation addressed in IBD-specific PROMs 
ICF categories PROMs 
ICF code ICF title CGQL IBDQOL IBDSI IBDQ-32 IBDQ-9 RFIPC SIBDQ WPAI:CD 
d Activities and Participation    +     
d2 General tasks and demands         
d230 Carrying out daily routine        + 
d7 Interpersonal interactions and relationships   +      
d760 Family relationships  +       
d770 Intimate relationships   +   +   
d7702 Sexual relationships  +  +     
d8 Major life areas         
d820 School education  + + +     
d850 Remunerative employment  +  +    + 
d859 Work and employment, other specified and 
unspecified   +      
d9 Community, social and civic life     +    
d910 Community life  + + +   +  
d920 Recreation and leisure  + + +   +  
d9201 Sports  +  +   +  
CGQL Cleveland Global Quality of Life (Faszio Score); IBDQOL Inflammatory Bowel Disease Quality of Life Questionnaire; IBDSI IBD Stress Index; IBDQ-32 Inflammatory 
Bowel Disease Questionnaire; IBDQ-9 Inflammatory Bowel Disease Questionnaire short form; RFIPC Rating Form of IBD Patient Concerns; SIBDQ Short Inflammatory Bowel 
Disease Questionnaire; WPAI:CD Work Productivity and Activity Impairment: Crohn’s Disease. 
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Table 5 ICF categories of the component Environmental Factors addressed in IBD-specific PROMs 
ICF categories PROMs 
ICF code ICF title CGQL IBDQOL IBDSI IBDQ-32 IBDQ-9 RFIPC SIBDQ WPAI:CD 
e Environmental factors    +     
e1 Products and technology         
e1101 Drugs  +    +   
e1151 Assistive products and technology for personal 
use in daily living      +   
e1501 Design, construction and building products and 
technology for gaining access to facilities inside 
buildings for public use  +  +     
e165 Assets      +   
e4 Attitudes    +     
e5 Services, Systems and policies         
e580 Health services, systems and policies      +   
e5800 Health services      +   
CGQL Cleveland Global Quality of Life (Faszio Score); IBDQOL Inflammatory Bowel Disease Quality of Life Questionnaire; IBDSI IBD Stress Index; IBDQ-32 Inflammatory 
Bowel Disease Questionnaire; IBDQ-9 Inflammatory Bowel Disease Questionnaire short form; RFIPC Rating Form of IBD Patient Concerns; SIBDQ Short Inflammatory Bowel 
Disease Questionnaire; WPAI:CD Work Productivity and Activity Impairment: Crohn’s Disease. 
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Table 6 Other aspects addressed in IBD-specific PROMs 
Other aspects PROMs 
Coding Title CGQL IBDQOL IBDSI IBDQ-32 IBDQ-9 RFIPC SIBDQ WPAI:CD 
pf Personal factors  + + + + + +  
nd Not definable   +   +   
nd-hc Not definable: Health condition      +   
nd-gh Not definable: General health + +  + +    
nd-QoL Not definable: Overall quality of life +        
nc Not covered      +   
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5. Discussion 
This doctoral thesis provides an overview and comparison of IBD-specific PROMs 
with respect to their contents covered using the ICF as a reference. The examination 
of the PROMs' contents covered on the smallest possible units, namely, the items of 
the questionnaires. This offers a clear and precise picture of the addressed PROMs 
contents identified in this study and enables direct comparisons to be made. The 
results of the content comparison provide valuable information to facilitate and 
account for the selection of appropriate IBD-specific PROMs for different purposes of 
data collection in clinical and research settings. 
 
Clinicians and researchers who define the aspects they want to measure in terms of 
the ICF can directly use Tables 3 to 5 to look up which of the examined PROMs cover 
those aspects. For example, a researcher dealing with the question how IBD affects 
the sleep function of persons with IBD will find the ICF category 'b1342 Maintenance 
of sleep' in Table 3. In this table the researcher can see that the items of the IBDQOL 
and the IBDQ-32 address this area of functioning and might, therefore, present an 
adequate choice in this context. Thus, PROMs and their items can be easily matched 
to each other by using the ICF, thereby simplifying the selection of PROMs. 
 
Overall, the areas of functioning addressed in the items of the identified PROMs are 
very diverse. There are just 4 ICF categories out of the 45 ICF categories linked to 
the 90 PROMs items that are addressed in at least 4 out of 8 PROMs. This indicates 
that the individual PROMs and their items differ widely in content. Examination of the 
PROMs' contents remarkably shows that a high percentage of the linked ICF 
categories applies to only two of the eight selected PROMs, namely IBDQOL and 
IBDQ-32. This means that many topics are addressed in these two PROMs, and no 
other PROMs include them. 
 
An important finding of this study refers to the representation of pain in IBD. Only 
three PROMs (IBDQ-32, RFIPC, SIBDQ) include items addressing sensory functions 
and pain, even if in clinical practice pain is stated in the case history of many persons 
diagnosed with IBD.41,42 Bielefeldt and colleagues show that not only inflammation, 
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but also bowel obstructions, can manifest as pain, and even a subgroup of IBD 
patients without evidence of overt inflammation, obstruction or other clinically defined 
abnormalities continue to have pain. Thus, pain or fear of pain constitute a significant 
burden for persons with IBD and can reduce their quality of life.43,44 
 
One of the most frequently covered ICF categories is 'b1300 Energy level'. Rooy and 
colleagues point out that the level of energy is the most intense concern of persons 
with IBD if the RFIPC is used as a PROM for examination.42  
 
In three PROMs ‘b152 Emotional functions’, which includes feelings like sadness, 
happiness, anxiety or sorrow, is covered (IBDQOL, IBDQ-32, SIBDQ). Whereas 
‘b1801 body image’ which includes the feeling of being too fat or too thin is 
represented in only one PROM (IBDSI). Muller and colleagues show that the majority 
of persons with IBD report that the disease affects their body image; particularly 
females who have had abdominal surgery describe a negative impact on their body 
image.45 
 
The question about maintenance of sleep or the quality of sleep is addressed in only 
two PROMs. Considering the fact persons with IBD complained of repeated 
awakening at night twice as often as healthy controls46 this area of functioning is 
poorly represented in the identified PROMs. A healthy sleep-wake cycle is critical for 
the regulation of immune and neuroendocrine functions47, and sleepiness and fatigue 
are often the cardinal manifestations of acute inflammatory disorders44. For persons 
with IBD, repeated awakenings are, among other reasons, attributed to the need to 
use the bathroom. A further important finding of this study is that none of the 
identified PROMs and their items covered the category 'd530 Toileting' which refers 
to coordinating and managing defecation and getting to an appropriate place for 
defecation. Stjernman and colleagues show that persons with IBD are often 
concerned about their loss of bowel control and are worried about finding a toilet in 
time.48 
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It is interesting that only 13 categories of the component Activities and Participation 
were linked to the items of the IBD-specific PROMs. In a qualitative study Peyrin-
Biroulet and colleagues show that various aspects of activities and participation (e.g., 
sexual relationships, managing diet and fitness, remunerative employment) are 
important from the patient perspective.49 These areas are poorly represented in IBD-
specific PROMs. However, some of the identified PROMs and their items (IBDQOL, 
IBDQ-32, IBDSI) cover a few ICF categories addressing activities of daily living and 
social participation: interpersonal interactions, work or school education or 
community, social and civic life.  
 
It could be argued that the results of this investigation suggest that the lack of 
coverage of important areas by the IBD-specific PROMs could be compensated by 
the joint use of IBD-specific and generic PROMs, such as the 36-Item Short Form 
Survey (SF-36).50 However, a comparison of the results of this study with the results 
of a previous one, in which the similarities and differences in content of the most 
widely used generic PROMs were studied, shows that these PROMs are very 
heterogeneous and that, as is the case in the condition-specific PROMs, they 
frequently do not cover some important areas in IBD, such as toileting and 
sexuality51. Toileting is only covered in the Spitzer’s Quality of Life Index (QL-I)52 and 
intimate relationships and sexuality only in the WHO Quality of Life-BREF 
(WHOQOL-BREF)53, World Health Organization Disability Assessment Schedule II 
(WHODAS II)54 and Nottingham Health Profile (NHP)55. The generic PROMs 
analysed in the mentioned study show a very high level of depth of coverage and 
granularity in mobility, which is a less relevant area in IBD. This comparison suggests 
that when selecting instruments for an investigation a very careful study of the 
contents of both the IBD-specific and generic PROMs is necessary to ensure that all 
relevant aspects of IBD and all study endpoints are covered without imposing 
unnecessary burden on the patients. The study of the psychometric properties is also 
important. For example, McColl et al. recommend the use of both types of PROMs in 
parallel based on the comparison of the discriminatory power of the SF-36 and the 
IBDQ.56 While disease activity was more highly correlated with IBDQ scores than 
with SF-36 scores, significant differences with respect to disease severity were found 
in the SF-36's energy/fatigue and social-function scales.  
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Last but not least, an ICF-based examination of the PROMs' contents could facilitate 
the development of new or modified PROMs. Presenting an overview of the most- or 
least-frequently mentioned ICF categories covering the items of the identified 
PROMs this paper could be used to identify areas of functioning and health. This 
information could lead to the development of more specific PROMs for clinical 
evaluation and research in IBD.  
 
The study has several limitations that have to be mentioned. The systematic literature 
review used to identify IBD-specific PROMs was based on a simplified review 
method using specific, rather than sensitive, search strategies. For practicability 
reasons, the number of abstracts to be checked was decreased by a random 
selection. Moreover, we largely relied on information contained in abstracts. We did 
not consider other outcome measures reported in the full-text articles of the retrieved 
studies (e.g. disease classifications or indices). However, in comparison to other 
reviews on PROMs in IBD,18,57 the PROMs identified in this paper cover the most 
frequently used and established PROMs in IBD. 
 
In this doctoral thesis the contents of IBD-specific PROMs and their items were 
examined to provide an overview of the areas of functioning and disability addressed 
by these PROMs using the ICF as a reference. This overview should facilitate the 
selection of PROMs in clinical practice and research. This study does not claim to be 
complete in terms of the frequencies of the identified PROMs. It is a first proposal to 
introduce a new tool, the ICF, for content comparison among IBD-specific PROMs 
and described its advantages by means of the given analyses. The method still can 
be explained without having analyzed all possibly available full-text articles. Finally, 
the linking process was performed by two medical doctors trained in the ICF and the 
application of the linking rules. However, it remains unclear whether other health 
professionals would have decided differently. 
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6. Conclusion 
An overview that examines the content of IBD-specific PROMs using the ICF as a 
reference has not been published so far. This doctoral thesis offers a clear and 
precise picture of the addressed PROMs and their contents and enable physicians 
and researchers a direct comparison of these contents. The ICF provides a useful 
framework for examining and comparing IBD-specific PROMs and their items with 
respect to the areas of functioning and disability covered. This information can be 
useful in selecting PROMs for clinical practice, as well as for any kind of 
investigations in which functioning and disability of persons with IBD is a relevant 
study outcome. None of the PROMs identified in this study is ideal for all 
applications. However, after having decided on “what should be measured”, this 
study may well assist clinicians and researchers in deciding on the most suitable 
PROM. The results of this study emphasize the need for a comprehensive PROM 
covering the whole spectrum of functioning and disability in IBD. 
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10. Appendix 
 
Appendix 1 Eligibility criteria 
 
Inclusion criteria Exclusion criteria 
Formal criteria  
Publication type: Journal article (original paper) Review (Topic Overview) or Meta-Analyses 
Comment 
Letter 
Editorial 
Guideline 
Conference Report 
Book chapter 
Dissertation 
Language: English Other than English 
Year of publication: 1999-2009 Other than 1999-2009 
Multiple publications:           
Journal with the highest impact factor in the 
case of multiple publications; the most recent 
publication will be considered 
 
Journal with lower than the highest impact factor in 
the case of multiple publications; the less recent 
publications will be excluded 
 Study design  
• Randomized controlled trial or randomized 
clinical trial (RCT) 
• Clinical controlled trial (CCT) 
• Cross-sectional study 
• Longitudinal observational study 
• Qualitative study 
• Psychometric study 
• Diagnostic efficacy evaluation 
• Register study 
• Chart review 
• Review or Meta-Analysis 
• Case report/ Case series 
• Primary prevention study 
• Clinical trials phase-I /-II study 
• Ecologic study 
• Economic evaluation study or decision analysis 
(costs, cost/benefit, cost/ effectiveness, cost/utility, 
modeling, simulation) based on review or meta-
analyses  
• Study protocol 
Study population  
Human Non-human population (animal study/ cadaver study/ 
genetic study/ exclusively laboratory-parameters/ in-
vitro study) 
Patients at age ≥ 18 yrs Patients at age <18 yrs 
Sample size: N ≥ 11 Sample Size: N ≤ 10 
Diagnosis: 
Patients with inflammatory bowel diseases; main 
diagnosis according  to ICD-10 at the beginning 
of data collection: 
K50  Crohn's disease [regional enteritis]         
       .0  Crohn's disease of small intestine  
       .1  Crohn's disease of large intestine  
       .8  Other Crohn's disease 
       .9  Crohn's disease, unspecified  
    K51      Ulcerative colitis  
       .0    Ulcerative (chronic) enterocolitis  
  .1    Ulcerative (chronic) ileocolitis 
 
Patients with inflammatory bowel diseases; main 
diagnosis according  to ICD-10 
K51.4  Pseudopolyposis of colon  
K51.5  Mucosal proctocolitis 
 Patients included in the sample with main disease 
conditions any other than target condition at study 
beginning, i.e. mixed patient population  (e.g. 
population consists of patients with diabetes or 
healthy controls) 
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Appendix 2  Example of a linked PROM 
 
Name of 
PROM 
Item Nr. Item as appeared in the questionnaire Linking first health professional Linking second health professional Linking final version 
   Linking unit ICF code Linking unit ICF code Linking unit ICF code 
IBDQ-9 1 How frequent have your bowel movements been 
during the last 2 weeks? 
Frequency of bowel movements  b5158 Frequency of bowel movements b539 Frequency of bowel movements b5150 
IBDQ-9 2 How often has the feeling of fatigue or of being 
tired and worn out been a problem for you during 
the last 2 weeks? 
- Feeling of fatigue 
 
- Feeling tired and worn out 
b1308 
 
b130 
Frequency of being tired b1308 - Feeling of fatigue 
 
- Feeling tired and worn out 
b1308 
 
b130 
IBDQ-9 3 How much energy have you had during the last 2 
weeks? 
Energy b1300 Energy level for the last 2 week b1300 Energy level for the last 2 week b1300 
IBDQ-9 4 How often during the last 2 weeks have you had 
to delay or cancel a social engagement because 
of your bowel problem? 
Delay or cancel a social engagement 
because of bowel problem 
d9108 Cancelling a social engagement 
 
nd Cancelling a social engagement d9 
IBDQ-9 5 How often during the last 2 weeks have you been 
troubled by cramps in your abdomen? 
Trouble by cramps in abdomen b5352 Abdominal cramp b5352 Abdominal cramp b5352 
IBDQ-9 6 How often during the last 2 weeks have you felt 
generally unwell? 
Feeling generally unwell gh Well-being pf Well being gh 
IBDQ-9 7 Overall, in the last 2 weeks, how much of a 
problem have you had with passing a large 
amount of gas? 
Large amount of gas b5254 Passing gas b5254 Passing gas b5254 
IBDQ-9 8 How much of the time during the last 2 weeks 
have you been troubled by feeling nauseated or 
sick with your stomach? 
- Feeling of nausea 
 
- Feeling of sick with stomach 
b5350 
 
b535 
Nausea b5350 - Feeling of sick with stomach 
 
- Nausea 
b535 
 
 
b5350 
IBDQ-9 9 How satisfied, happy, or pleased have you been 
with your personal life during the last 2 weeks? 
Satisfaction with personal life 
 
Happieness with personal life 
pf 
 
 
d 
General well-being pf Satisfaction with personal life pf 
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